Market Tracker

02/24 12:19pm ET

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

3.05
BATS BZX Real-Time Price
As of 12:18pm ET
 -0.01 / -0.33%
Today’s Change
2.83
Today|||52-Week Range
9.02
-25.25%
Year-to-Date
Merrimack (MACK): What Awaits the Stock in Q4 Earnings?
Feb 17 / Zacks.com - Paid Partner Content
3 Stocks Begging for a Buyout
Feb 11 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close3.06
Today’s open3.04
Day’s range3.02 - 3.08
Volume74,298
Average volume (3 months)3,502,144
Market cap$396.6M
Dividend yield--
Data as of 12:18pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-66.25%
Earnings growth (this year)+12.28%
Earnings growth (next 5 years)+5.61%
Revenue growth (last year)-13.14%
P/E ratioNM
Price/Sales9.86
Price/Book--

Competitors

 Today’s
change
Today’s
% change
CARACara Therapeutics In...+0.29+1.99%
AQXPAquinox Pharmaceutic...-0.14-0.83%
OBSVObseva SA-0.24-1.79%
TLGTTeligent Inc+0.07+0.96%
Data as of 12:18pm ET, 02/24/2017

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)-$0.21
Annual revenue (last year)$89.3M
Annual profit (last year)-$148.0M
Net profit margin-165.76%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer
Richard Peters
Head-
Corporate Operations
William M. McClements
Corporate headquarters
Cambridge, Massachusetts

Forecasts